Presence of asymmetric dimethylarginine gradients across high-grade lesions in patients with coronary artery disease

Coronary Artery Disease

Volumn 18, Issue 6, 2007, Pages 471-475

  Joyal, Dominique ^a   Leya, Ferdinand ^a   Obada Al Chekakie, M ^a   Arab, Dinesh ^a   Dieter, Robert S ^a   Morshedi Meibodi, Ali ^a   Lewis, Bruce ^a   Steen, Lowell ^a   Fareed, Jawed ^a   Hoppenstead, Debra ^a   Akar, Joseph G ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Atherosclerosis; Endothelium; Nitric oxide; Nitric oxide synthase

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTERY LESION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VEIN; PRIORITY JOURNAL;

AGED; ANGIOPLASTY, BALLOON, LASER-ASSISTED; ARGININE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 34547899138     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32818be79c     Document Type: Article

References (27)

1. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48:489-509.
2. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339:572-575.
3. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24:1023-1030.
4. Weidinger FF, McLenachan JM, Cybulsky M, Gordon JB, Rennke HG, Hollenberg NK, et al. Persistent dysfunction of regenerated endothelium following balloon angioplasty of rabbit iliac artery. Circulation 1990; 81:1667-1679.
5. Masuda H, Goto M, Tamaoki S, Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 1999; 126:211-218.
6. Zoccali C, Bode-Boger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L, et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 2001; 358:2113-2117.
7. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97:e53-e59.
8. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26:1235-1241.
9. Teragawa H, Ueda K, Matsuda K, Kimura M, Higashi Y, Oshima T, et al. Relationship between endothelial function in the coronary and brachial arteries. Clin Cardiol 2005; 28:460-466.
10. Candipan RC, Wang B, Buitrago R, Tsao PS, Cooke JP. Regression or progression: dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 1996; 16:44-50.
11. Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP, et al. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 1997; 95:1863.
12. Wilson RF, Laxson DD, Lesser JR, White CW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989;1:807-811.
13. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99:1141-1146.
14. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287:1420-1426.
15. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88:1201-1203.
16. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15:901-909.
17. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1557-1564.
18. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessel 2003; 18:177-182.
19. Nijveldt RJ, van Leeuwen PAM, van Guldener C, Stehouwer CDA, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 2002; 17:1999-2002.
20. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetric dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003; 24:1912-1919.
21. Maas R, Quitzau K, Schwedhelma E, Spieker L, Rafflenbeul W, Steenpaß A, et al. Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. Atherosclerosis 2007; 191:211-219.
22. Caramori PR, Lima VC, Seidelin PH, Newton GE, Parker JD, Adelman AG. Long-term endothelial dysfunction after coronary artery stenting. J Am Coll Cardiol 1999; 34:1675-1679.
23. Hofma SH, Whelan DM, van Beusekom HM, Verdouw PD, van der Giessen WJ. Increasing arterial wall injury after long-term implantation of qtwo types of stent in a porcine coronary model. Eur Heart J 1998; 19:601-609.
24. Shimokawa H, Flavahan NA, Shepherd JT, Vanhoutte PM. Endothelium- dependent inhibition of ergonovine-induced contraction is impaired in porcine coronary arteries with regenerated endothelium. Circulation 1989; 80:643-650.
25. Cox RH, Haas KS, Moisey DM, Tulenko TN. Effects of endothelium regeneration on canine coronary artery function. Am J Physiol 1989; 257(5 Pt 2):H1681-H1692.
26. Suter TM, Buechi M, Hess OM, Haemmerli-Saner C, Gaglione A, Krayenbuehl HP. Normalization of coronary vasomotion after percutaneous transluminal coronary angioplasty? Circulation 1992; 85:86-92.
27. McFadden EP, Bauters C, Lablanche JM, Quandalle P, Leroy F, Bertrand ME. Response of human coronary arteries to serotonin after injury by coronary angioplasty. Circulation 1993; 88:2076-2085.